Profound Medical Corp.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
PROF$7.68+4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEET****S
(USD in thousands, except per share data)
| | | | | |
|---|---|---|---|---|
| | | September 30, | | December 31, |
| | | 2026 | | 2025 |
| | | $ | | $ |
| Assets | | | | |
| | | | | |
| Current assets: | | | | |
| Cash | | 33,343 | 59,723 | |
| Trade and other receivables, net (note 3) | | 10,991 | 7,200 | |
| Inventory (note 4) | | 10,242 | 8,238 | |
| Prepaid expenses and deposits | | 253 | 928 | |
| Total current assets | | 54,829 | 76,089 | |
| | | | | |
| Trade and other receivables, net (note 3) | | — | | 300 |
| Property and equipment, net (note 5) | | 430 | 698 | |
| Intangible assets, net (note 6) | | 115 | 138 | |
| Right-of-use assets, net (note 9) | | 2,687 | 184 | |
| Deferred tax assets, net | | 93 | | 66 |
| Total assets | | 58,154 | 77,475 | |
| | | | | |
| Liabilities | | | | |
| | | | | |
| Current liabilities: | | | | |
| Accounts payable | | 1,048 | 1,563 | |
| Accrued expenses and other current liabilities (note 7) | | 5,517 | 3,815 | |
| Deferred revenue | | 805 | 445 | |
| Long-term debt (note 8) | | 4,512 | — | |
| Lease liabilities (note 9) | | 105 | 213 | |
| Income tax payable | | 77 | 39 | |
| Total current liabilities | | 12,064 | 6,075 | |
| | | | | |
| Deferred revenue | | 743 | 388 | |
| Long-term debt (note 8) | | — | 4,499 | |
| Lease liabilities (note 9) | | 2,741 | — | |
| Other non-current liabilities | | 93 | 79 | |
| Total liabilities | | 15,641 | 11,041 | |
| | | | | |
| Shareholders’ equity | | | | |
| | | | | |
| Common shares, no par value, unlimited shares authorized, 36,626,844 and 36,293,640 issued and outstanding at September 30, 2026 and December 31, 2025, respectively (note 10) | | 326,108 | 323,839 | |
| Additional paid-in capital | | 25,256 | 25,310 | |
| Accumulated other comprehensive income | | 3,204 | 5,025 | |
| Accumulated deficit | | (312,055) | (287,740) | |
| Total shareholders’ equity | | 42,513 | 66,434 | |
| | | | | |
| Total liabilities and shareholders’ equity | | 58,154 | 77,475 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.